RecruitingNCT06136546
Infliximab or placebo for thinking and movement speed during depression
About this title
Read the official source — NCT06136546Medication studyAges 25–50United States
Understand this study
Who could participate?
Listed age limits: 25 years to 50 years.
What will I do during this study?
You are randomly assigned to an intravenous infusion of infliximab or saline placebo (an inactive comparison treatment). Over two weeks of follow-up, you complete brief daily phone-based mood and thinking tasks as well as in-person assessments. Blood samples are taken at the start and at one week.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 23, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 25 Years to 50 Years
- Official registry ID
- NCT06136546
- Official title
Show the full official title
The Role of Inflammation in Cognitive Dysfunction in Acute Depression as Determined by Experimental Inhibition of Tumor Necrosis Factor-alpha Signaling in a Randomized Controlled Trial.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boston
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Infliximab.
Who can participate?
Listed age limits: 25 years to 50 years.
Is this study still recruiting?
The registry lists this study as recruiting.
